3/A//SEC Filing
Lev Pharmaceuticals Inc 3/A
Accession 0001209191-09-017647
CIK 0001144062operating
Filed
Mar 19, 8:00 PM ET
Accepted
Mar 20, 3:12 PM ET
Size
9.7 KB
Accession
0001209191-09-017647
Insider Transaction Report
Form 3/AAmended
Holdings
Common Stock Warrants (right to buy)
Exercise: $1.66From: 2007-11-02Exp: 2010-11-01→ Common Stock (900,000 underlying)- 15,718,400
Common Stock, $0.01 par value per share
Mast Capital Management LLC
10% Owner
Holdings
Common Stock Warrants (right to buy)
Exercise: $1.66From: 2007-11-02Exp: 2010-11-01→ Common Stock (900,000 underlying)- 15,718,400
Common Stock, $0.01 par value per share
Footnotes (4)
- [F1]This amendment to Form 3 is being filed to correct the number of non-derivative securities reported as beneficially owned by the Reporting Persons in the original Form 3 filing. The original Form 3 disclosed in Table I that the Reporting Persons beneficially owned 16,618,400 shares of common stock, which number erroneously included 900,000 shares of common stock issuable upon exercise of a warrant that should have been reported as derivative securities in Table II of the original Form 3. This amendment reports in Table I, column 2 the number of outstanding shares of common stock held by the Reporting Persons as of March 18, 2008, excluding the 900,000 shares of common stock subject to such warrant. The 900,000 shares of common stock subject to such warrant were similarly included in Table 1 on three Forms 4 filed by the Reporting Persons after the original Form 3 was filed.
- [F2]Mast Credit Opportunities I Master Fund Limited (the "Fund") is the direct owner of 15,718,400 shares of common stock of the Issuer. For purposes of Rule 13d-3, Mast Capital Management, LLC is the indirect beneficial owner of such shares as a result of its service as the investment adviser to the Fund. Each of the Reporting Persons disclaims beneficial ownership of such shares of the Issuer except to the extent of its pecuniary interest therein, if any.
- [F3]This amendment to Form 3 is being filed to report on Table II 900,000 shares of common stock issuable upon exercise of a warrant which were erroneously included in Table I of the original Form 3. This amendment reports in Table II, column 3 the number of shares of common stock subject to such warrant held by the Reporting Persons as of March 18, 2008.
- [F4]The Fund is the direct owner of a warrant to purchase 900,000 shares of common stock of the Issuer. For purposes of Rule 13d-3, Mast Capital Management, LLC is the indirect beneficial owner of the shares underlying such warrant as a result of its service as the investment adviser to the Fund. Each of the Reporting Persons disclaims beneficial ownership of such shares of the Issuer except to the extent of its pecuniary interest therein, if any.
Documents
Issuer
Lev Pharmaceuticals Inc
CIK 0001144062
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001144062
Filing Metadata
- Form type
- 3/A
- Filed
- Mar 19, 8:00 PM ET
- Accepted
- Mar 20, 3:12 PM ET
- Size
- 9.7 KB